Publications by authors named "Roger Trinh"

Claim this Profile
G
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Robert S Brown, Maria Buti, Lino Rodrigues, Vladimir Chulanov, Wan-Long Chuang, Roger Trinh

J Hepatol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Robert J Fontana, Sabela Lens, Stuart McPherson, Magdy Elkhashab, Victor Ankoma-Sey, Roger Trinh

Adv Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
Graham R Foster, Tarik Asselah, Sarah Kopecky-Bromberg, Yang Lei, Armen Asatryan, Roger Trinh

PLoS One· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Fred Poordad, Shahriar Sedghi, Paul J Pockros, Natarajan Ravendhran, Robert Reindollar, Roger Trinh

J Viral Hepat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Steven Flamm, David Mutimer, Armen Asatryan, Stanley Wang, Jürgen Rockstroh, Roger Trinh

J Viral Hepat· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Nancy Reau, Paul Y Kwo, Susan Rhee, Robert S Brown, Kosh Agarwal, Roger Trinh

Hepatology· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Jürgen K Rockstroh, Karine Lacombe, Rolando M Viani, Chloe Orkin, David Wyles, Roger Trinh

Clin Infect Dis· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study to Evaluate the Effect of Crushing, Cutting Into Half, or Grinding of Glecaprevir/Pibrentasvir Tablets on Exposures in Healthy Subjects.
Rajneet K Oberoi, Weihan Zhao, Dilraj S Sidhu, Rolando M Viani, Roger Trinh

J Pharm Sci· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Stefan Zeuzem, Graham R Foster, Stanley Wang, Armen Asatryan, Edward Gane, Roger Trinh

N Engl J Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, David Wyles, Anne F Luetkemeyer, Roger Trinh

Open Forum Infect Dis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
Jennifer R King, Amit Khatri, Roger Trinh, Rolando M Viani, Bifeng Ding

Antimicrob Agents Chemother· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
David Wyles, Michael Saag, Rolando M Viani, Jacob Lalezari, Oluwatoyin Adeyemi, Roger Trinh

J Infect Dis· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Amit Khatri, Roger Trinh, Weihan Zhao, Thomas Podsadecki, Rajeev Menon

Antimicrob Agents Chemother· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Amit Khatri, Sandeep Dutta, Martin Dunbar, Thomas Podsadecki, Roger Trinh

Antimicrob Agents Chemother· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Amit Khatri, Sandeep Dutta, Haoyu Wang, Thomas Podsadecki, Roger Trinh

Clin Infect Dis· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Jordan J Feld, Christophe Moreno, Roger Trinh, Edward Tam, Stefan Bourgeois

J Hepatol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Joseph J Eron, Jay Lalezari, Jihad Slim, Joseph Gathe, Peter J Ruane, Roger Trinh

J Int AIDS Soc· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Xavier Forns, Fred Poordad, Marcos Pedrosa, Marina Berenguer, Heiner Wedemeyer, Roger Trinh

Liver Int· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Mark S Sulkowski, Joseph J Eron, David Wyles, Roger Trinh, Jay Lalezari

JAMA· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Fred Poordad, Christophe Hezode, Roger Trinh, Kris V Kowdley, Stefan Zeuzem

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.
Thomas P Young, Laura A Napolitano, Agnes C Paquet, Neil T Parkin, Signe Fransen, Roger Trinh

J Virol Methods· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
Jacques Reynes, Roger Trinh, Federico Pulido, Ruth Soto-Malave, Joseph Gathe

AIDS Res Hum Retroviruses· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Thomas P Young, Neil T Parkin, Eric Stawiski, Tami Pilot-Matias, Roger Trinh

Antimicrob Agents Chemother· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis